- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02903277
National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
15 de junho de 2026 atualizado por: Centre Hospitalier Universitaire de Nice
The median age of onset of chronic myeloid leukemia (CML) in chronic phase PC is about 60 years.
However CML affects all age groups including 18-25 year olds, called adult-young adolescents (AJA).
In France, there is no record of CML and especially not for this particular population, only a European Register of CML in children up to 18 years has been set up under the coordination of Professor "Frederic Millot", pediatrics, CHU Poitiers.
Malignancies diagnosed in this population usually have characteristics, evolution, therapeutic strategies with tyrosine kinase inhibitors (TKIs) are a real therapeutic revolution with an overall survival very significantly augmented but at present only a minority of patients may one day consider a final judgment of treatment.
AJA are the most exposed patients to the complications, the socio-economic repercussions, professional and personal of a very long-term treatment.
But there is little data in the literature concerning this population.
Two studies show that diagnosis of CML presents with poor prognostic factors (high skoal), the observed responses are poorer compared to older patients but it is accompanied difference in survival in all cases with a decline of about 70 mois.
However, these studies have focused solely on the patients included in the study receiving optimized treatment is not the standard treatment at the time.
It is clearly demonstrated that the inclusion in a study brings a benefit to the patient.
However, the majority of AJA are not included in a study.
The investigators therefore want to describe the AYA population of CML in France and compare the evolution of patients included or not in a protocol.
The investigators also want to investigate specific issues of the age of these patients as the reproductive desire.
Indeed, while it does not seem to be any risk of teratogenicity for men treated with ITK, this risk is clearly established for women and requires specific supported.
Another important point is that of the quality of life.
The state of physical and mental health and his feelings, physical activity and its limitations and well-being was assessed by the SF-3612 questionnaire.
The results of this analysis were compared with those already obtained for the general population (not representative of Italian adults with cancer sample) and adjusted for sex, age, geographic region, marital status and education level .
There seems to be young people and women who express a feeling more pejorative.
This does not only covers the frequency of side effects but also on physical activity and well-being.
the affected population will be noted that that is particularly involved in the social, professional and in the development of his personal life.
The impact of treatment on quality of life must be considered under penalty of seeing the difficulties of compliance.
But several studies have demonstrated the negative impact of poor adherence in response to treatments .
Visão geral do estudo
Status
Retirado
Tipo de estudo
Observacional
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 30 anos (Adulto)
Aceita Voluntários Saudáveis
Não
Método de amostragem
Amostra Não Probabilística
População do estudo
All patients aged 18 to 30 years diagnosed with CML treated with a frontline ITK will be included in the observatory after collecting their non-opposition.
In the retrospective part of the study, we will collect data from dead or lost to patients.
Descrição
Inclusion Criteria:
- patients aged 18 to 30 years
- patients diagnosed with CML treated with TKI first line
- collecting their non-opposition
Exclusion Criteria:
- none
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Collect clinical data of diagnosis of the AJA CML patients
Prazo: Change from the inclusion at modification of treatment
|
Describe the characteristics of the AJA CML patients (18-30 years) in terms of presentation at diagnosis, treatment choices, tolerance, adherence to therapeutic response, evolution and survival.
|
Change from the inclusion at modification of treatment
|
|
Treatment choices of the AJA CML patients
Prazo: Change from the inclusion at modification of treatment
|
Describe the characteristics of the AJA CML patients (18-30 years) in terms of presentation at diagnosis, treatment choices, tolerance, adherence to therapeutic response, evolution and survival.
|
Change from the inclusion at modification of treatment
|
|
Tolerance of treatments
Prazo: Change from the inclusion at modification of treatment
|
Describe the characteristics of the AJA CML patients (18-30 years) in terms of presentation at diagnosis, treatment choices, tolerance, adherence to therapeutic response, evolution and survival.
|
Change from the inclusion at modification of treatment
|
|
Adherence to therapeutic response
Prazo: Change from the inclusion at modification of treatment
|
Describe the characteristics of the AJA CML patients (18-30 years) in terms of presentation at diagnosis, treatment choices, tolerance, adherence to therapeutic response, evolution and survival.
|
Change from the inclusion at modification of treatment
|
|
Evolution of the disease
Prazo: Change from the inclusion at modification of treatment
|
Describe the characteristics of the AJA CML patients (18-30 years) in terms of presentation at diagnosis, treatment choices, tolerance, adherence to therapeutic response, evolution and survival.
|
Change from the inclusion at modification of treatment
|
|
Survival of the patient
Prazo: Change from the inclusion at modification of treatment
|
Describe the characteristics of the AJA CML patients (18-30 years) in terms of presentation at diagnosis, treatment choices, tolerance, adherence to therapeutic response, evolution and survival.
|
Change from the inclusion at modification of treatment
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de novembro de 2016
Conclusão Primária (Real)
2 de janeiro de 2017
Conclusão do estudo (Real)
2 de janeiro de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
21 de julho de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
12 de setembro de 2016
Primeira postagem (Estimado)
16 de setembro de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
16 de junho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
15 de junho de 2026
Última verificação
1 de junho de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias
- Doença crônica
- Atributos da doença
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Leucemia Mieloide
- Doenças da Medula Óssea
- Leucemia
- Distúrbios mieloproliferativos
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Leucemia Mielóide, Crônica, BCR-ABL Positivo
Outros números de identificação do estudo
- 14-PP-10
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .